IL139220A0 - Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection - Google Patents

Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection

Info

Publication number
IL139220A0
IL139220A0 IL13922099A IL13922099A IL139220A0 IL 139220 A0 IL139220 A0 IL 139220A0 IL 13922099 A IL13922099 A IL 13922099A IL 13922099 A IL13922099 A IL 13922099A IL 139220 A0 IL139220 A0 IL 139220A0
Authority
IL
Israel
Prior art keywords
ribavirin
infection
combination therapy
interferon alpha
chronic hepatitis
Prior art date
Application number
IL13922099A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL139220(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL139220A0 publication Critical patent/IL139220A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL13922099A 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection IL139220A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15
PCT/US1999/007037 WO1999059621A1 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
IL139220A0 true IL139220A0 (en) 2001-11-25

Family

ID=22151354

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13922099A IL139220A0 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
IL139220A IL139220A (en) 1998-05-15 2000-10-23 Use of ribavirin for preparing a pharmaceutical composition for treating in combination with interferon alpha naive patients having chronic hepatitis c infection
IL207259A IL207259A (en) 1998-05-15 2010-07-27 Use of drugs that include, inter alia, ribavirin and interferon alfa for the treatment of chronic hepatitis C patients not previously treated with antiviral therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL139220A IL139220A (en) 1998-05-15 2000-10-23 Use of ribavirin for preparing a pharmaceutical composition for treating in combination with interferon alpha naive patients having chronic hepatitis c infection
IL207259A IL207259A (en) 1998-05-15 2010-07-27 Use of drugs that include, inter alia, ribavirin and interferon alfa for the treatment of chronic hepatitis C patients not previously treated with antiviral therapy

Country Status (22)

Country Link
EP (3) EP0956861B1 (https=)
JP (2) JP5281726B2 (https=)
KR (1) KR100694345B1 (https=)
CN (1) CN1230198C (https=)
AR (1) AR019551A1 (https=)
AT (1) ATE216591T1 (https=)
AU (2) AU766597B2 (https=)
BR (1) BR9910505A (https=)
CA (1) CA2331823A1 (https=)
CZ (1) CZ300540B6 (https=)
DE (1) DE69901321T2 (https=)
DK (1) DK0956861T3 (https=)
ES (1) ES2172288T3 (https=)
HU (1) HU230432B1 (https=)
IL (3) IL139220A0 (https=)
MY (1) MY129244A (https=)
NO (1) NO330715B1 (https=)
NZ (1) NZ507621A (https=)
PT (1) PT956861E (https=)
SK (1) SK288038B6 (https=)
TW (1) TWI277424B (https=)
WO (1) WO1999059621A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO2000037110A2 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
CA2384326A1 (en) * 1999-12-23 2001-06-28 Johnson Lau Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
AU2002213343A1 (en) * 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
CA2466228A1 (en) * 2001-11-09 2003-08-07 Biomedicines, Inc. Method for treating diseases with omega interferon
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
CA2520148A1 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
EP1613342A1 (en) * 2003-04-17 2006-01-11 Ares Trading S.A. Interferon beta in severe acute respiratory syndrome (sars)
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US7482149B2 (en) * 2003-06-09 2009-01-27 Genome Institute Of Singapore Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
TW201424733A (zh) * 2004-10-29 2014-07-01 Vertex Pharma 劑量型式
CA2636527C (en) * 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009015336A2 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
RU2369403C1 (ru) * 2008-05-22 2009-10-10 Сергей Юрьевич Родионов Способ лечения хронических вирусных гепатитов
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
CN103179974A (zh) * 2010-10-05 2013-06-26 诺华有限公司 丙型肝炎病毒感染的新疗法
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EP2680859B1 (en) * 2011-03-02 2022-04-27 Jerome Schentag Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
DE69632062T2 (de) * 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
WO1999008729A1 (en) 1997-08-13 1999-02-25 Boston Scientific Limited Loading and release of water-insoluble drugs
ES2186660T3 (es) * 1997-09-21 2003-05-16 Schering Corp Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.

Also Published As

Publication number Publication date
KR100694345B1 (ko) 2007-03-12
NO20005755D0 (no) 2000-11-14
CN1230198C (zh) 2005-12-07
EP1213029A1 (en) 2002-06-12
AU2005220271B9 (en) 2010-12-09
CN1309568A (zh) 2001-08-22
HUP0103423A3 (en) 2003-11-28
AU2005220271A1 (en) 2005-11-03
PT956861E (pt) 2002-08-30
NO20005755L (no) 2001-01-12
CZ20004177A3 (cs) 2001-04-11
DE69901321T2 (de) 2002-12-12
JP2011173898A (ja) 2011-09-08
HU230432B1 (hu) 2016-06-28
EP2305287A1 (en) 2011-04-06
AU3860099A (en) 1999-12-06
SK288038B6 (en) 2013-01-02
NO330715B1 (no) 2011-06-20
AR019551A1 (es) 2002-02-27
IL207259A (en) 2016-08-31
AU2005220271B8 (en) 2010-11-18
BR9910505A (pt) 2001-01-02
HUP0103423A2 (hu) 2002-01-28
ES2172288T3 (es) 2002-09-16
JP2002515453A (ja) 2002-05-28
IL207259A0 (en) 2010-12-30
CZ300540B6 (cs) 2009-06-10
CA2331823A1 (en) 1999-11-25
NZ507621A (en) 2002-11-26
AU766597B2 (en) 2003-10-16
AU2005220271B2 (en) 2005-11-03
EP0956861A1 (en) 1999-11-17
WO1999059621A1 (en) 1999-11-25
JP5281726B2 (ja) 2013-09-04
MY129244A (en) 2007-03-30
HK1021131A1 (en) 2000-06-02
KR20010043624A (ko) 2001-05-25
IL139220A (en) 2013-02-28
DK0956861T3 (da) 2002-07-01
DE69901321D1 (de) 2002-05-29
ATE216591T1 (de) 2002-05-15
TWI277424B (en) 2007-04-01
EP0956861B1 (en) 2002-04-24
SK17102000A3 (sk) 2001-05-10

Similar Documents

Publication Publication Date Title
IL139220A0 (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
HUP0100092A3 (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
IL139786A0 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
NO20031742L (no) HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
AU6588598A (en) Treatment of hepatitis b infection with thymosin alpha 1 and famciclovir
EP0818976A4 (en) DISPOSABLE MASK AND SUCTION CATHETER
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
ID24910A (id) Karboksilat nukleosid hemisulfat dan penggunaan dalam perlakuan infeksi viral
PL311031A1 (en) Use of concentrates comprising vwf in complex therapy in case of treatment by using anticoagulants and fibrinolitic drugs
IL92161A0 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
EP1224939A4 (en) INTERFERON-BASED COMPLEX AND ITS USE IN MEDICINE
AU3857389A (en) Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon
ZA988519B (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
SI1311279T1 (sl) Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom
AU8353601A (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
HUP0200731A3 (en) Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy
SI1077068T1 (en) Utilization of interferon alpha 5 in the treatment of viral hepatopathies
EP1908477A3 (en) Combination of temozolomide and pegylated interferon-alpha for treating cancer
GB9725480D0 (en) Cytokines and their use in the treatment of established chronic infections and cancers
GB8901034D0 (en) Improvements in and relating to suction treatment of the body